{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:11:08Z","timestamp":1784045468467,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2028652"],"award-info":[{"award-number":["2028652"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2028652"],"award-info":[{"award-number":["2028652"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2028652"],"award-info":[{"award-number":["2028652"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-026-04061-y","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:35:57Z","timestamp":1779356157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cIntranasal clozapine sol-gel formulation induces an antipsychotic effect at a fraction of a comparable oral therapeutic dose\u201d"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5023-7095","authenticated-orcid":false,"given":"DW","family":"Eyles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HS","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"D.","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8783-845X","authenticated-orcid":false,"given":"M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3495-5943","authenticated-orcid":false,"given":"M.","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5328-5087","authenticated-orcid":false,"given":"X.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"4061_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"4061_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2215-0366(25)00031-8","volume":"12","author":"RA McCutcheon","year":"2025","unstructured":"McCutcheon RA, Pillinger T, Varvari I, Halstead S, Ayinde OO, Crossley NA, et al. INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia. Lancet Psychiatry. 2025;12:384\u201394.","journal-title":"Lancet Psychiatry"},{"key":"4061_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/acps.12700","volume":"135","author":"R Land","year":"2017","unstructured":"Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth SA. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017;135:296\u2013309.","journal-title":"Acta Psychiatr Scand"},{"key":"4061_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/schbul\/sby052","volume":"45","author":"JM Vermeulen","year":"2019","unstructured":"Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. 2019;45:315\u201329.","journal-title":"Schizophr Bull"},{"key":"4061_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/14740338.2024.2362796","volume":"23","author":"T Tanzer","year":"2024","unstructured":"Tanzer T, Pham B, Warren N, Barras M, Kisely S, Siskind D. Overcoming clozapine\u2019s adverse events: a narrative review of systematic reviews and meta-analyses. Expert Opin Drug Saf. 2024;23:811\u201331.","journal-title":"Expert Opin Drug Saf"},{"key":"4061_CR6","doi-asserted-by":"crossref","unstructured":"Lind L, Riserus U, Elmstahl S, Arnlov J, Michaelsson K, Titova OE. Combinations of BMI and metabolic syndrome and the risk of myocardial infarction, stroke, and heart failure. Nutr Metab Cardiovasc Dis. 2025;35:104102.","DOI":"10.1016\/j.numecd.2025.104102"},{"key":"4061_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","volume":"11","author":"K Northwood","year":"2024","unstructured":"Northwood K, Myles N, Clark SR, Every-Palmer S, Myles H, Kisely S, et al. Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study. Lancet Psychiatry. 2024;11:27\u201335.","journal-title":"Lancet Psychiatry"},{"key":"4061_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/acps.13159","volume":"141","author":"D Siskind","year":"2020","unstructured":"Siskind D, Nielsen J. Clozapine: a fine balance. Acta Psychiatr Scand. 2020;141:175\u20137.","journal-title":"Acta Psychiatr Scand"},{"key":"4061_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.schres.2018.05.046","volume":"201","author":"H Verdoux","year":"2018","unstructured":"Verdoux H, Quiles C, Bachmann CJ, Siskind D. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. Schizophr Res. 2018;201:10\u20139.","journal-title":"Schizophr Res"},{"key":"4061_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ebiom.2016.02.020","volume":"5","author":"S Every-Palmer","year":"2016","unstructured":"Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016;5:125\u201334.","journal-title":"EBioMedicine"},{"key":"4061_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/ijms17060863","volume":"17","author":"A Shirazi","year":"2016","unstructured":"Shirazi A, Stubbs B, Gomez L, Moore S, Gaughran F, Flanagan RJ, et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci. 2016;17:863.","journal-title":"Int J Mol Sci"},{"key":"4061_CR12","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1080\/10717544.2021.1951895","volume":"28","author":"S Sayed","year":"2021","unstructured":"Sayed S, Elsharkawy FM, Amin MM, Shamsel-Din HA, Ibrahim AB. Brain targeting efficiency of intranasal clozapine-loaded mixed micelles following radio labeling with Technetium-99m. Drug Deliv. 2021;28:1524\u201338.","journal-title":"Drug Deliv"},{"key":"4061_CR13","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3390\/pharmaceutics15051554","volume":"15","author":"R Lombardo","year":"2023","unstructured":"Lombardo R, Ruponen M, Rautio J, Ghelardini C, Di Cesare Mannelli L, Calosi L, et al. Development of lyophilised Eudragit((R)) retard nanoparticles for the sustained release of clozapine via intranasal administration. Pharmaceutics. 2023;15:1554.","journal-title":"Pharmaceutics"},{"key":"4061_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.113862","volume":"237","author":"HP Patel","year":"2024","unstructured":"Patel HP, Desai PH, Patel RV, Lodha SN, Gore AH, Patil PO, et al. Clozapine-laden carbon dots delivered to the brain via an intranasal pathway: synthesis, characterization, ex vivo, and in vivo studies. Colloids Surf B Biointerfaces. 2024;237:113862.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"4061_CR15","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/pharmaceutics16111417","volume":"16","author":"AA Katamesh","year":"2024","unstructured":"Katamesh AA, Abdel-Bar HM, Break MKB, Hassoun SM, Subaiea G, Radwan A, et al. Manipulation of lipid nanocapsules as an efficient intranasal platform for brain deposition of clozapine as an antipsychotic drug. Pharmaceutics. 2024;16:1417.","journal-title":"Pharmaceutics"},{"key":"4061_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/gels8010038","volume":"8","author":"MSA Tan","year":"2022","unstructured":"Tan MSA, Pandey P, Falconer JR, Siskind DJ, Balmanno A, Parekh HS. Clozapine-encapsulated binary mixed micelles in thermosensitive sol-gels for intranasal administration. Gels. 2022;8:38.","journal-title":"Gels"},{"key":"4061_CR17","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1021\/acs.molpharmaceut.2c00513","volume":"19","author":"MSA Tan","year":"2022","unstructured":"Tan MSA, Pandey P, Lohman R-J, Falconer JR, Siskind DJ, Parekh HS. Fabrication and characterization of clozapine nanoemulsion sol\u2013gel for intranasal administration. Mol Pharm. 2022;19:4055\u201366.","journal-title":"Mol Pharm"},{"key":"4061_CR18","unstructured":"Parekh H, Pandey P. Sol-gel composition. World Intellectual Property Organisation 2022; WO2022040751"},{"key":"4061_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2174\/138161210790170085","volume":"16","author":"ML Wadenberg","year":"2010","unstructured":"Wadenberg ML. Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des. 2010;16:358\u201370.","journal-title":"Curr Pharm Des"},{"key":"4061_CR20","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0149-7634(99)00037-8","volume":"23","author":"ML Wadenberg","year":"1999","unstructured":"Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neurosci Biobehav Rev. 1999;23:851\u201362.","journal-title":"Neurosci Biobehav Rev"},{"key":"4061_CR21","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/sj.npp.1300414","volume":"29","author":"A Smith","year":"2004","unstructured":"Smith A, Li M, Becker S, Kapur S. A model of antipsychotic action in conditioned avoidance: a computational approach. Neuropsychopharmacology. 2004;29:1040\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"4061_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.bbr.2013.09.050","volume":"257","author":"J Gao","year":"2013","unstructured":"Gao J, Li M. Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism. Behav Brain Res. 2013;257:286\u201394.","journal-title":"Behav Brain Res"},{"key":"4061_CR23","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00213-014-3756-2","volume":"232","author":"M Feng","year":"2015","unstructured":"Feng M, Gao J, Sui N, Li M. Effects of central activation of serotonin 5-HT2A\/2C or dopamine D 2\/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test. Psychopharmacology (Berl). 2015;232:1219\u201330.","journal-title":"Psychopharmacology (Berl)"},{"key":"4061_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s002130000466","volume":"150","author":"ML Wadenberg","year":"2000","unstructured":"Wadenberg ML, Kapur S, Soliman A, Jones C, Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl). 2000;150:422\u20139.","journal-title":"Psychopharmacology (Berl)"},{"key":"4061_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","volume":"25","author":"ML Wadenberg","year":"2001","unstructured":"Wadenberg ML, Soliman A, VanderSpek SC, Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 2001;25:633\u201341.","journal-title":"Neuropsychopharmacology"},{"key":"4061_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0269881116654697","volume":"30","author":"M Li","year":"2016","unstructured":"Li M. Antipsychotic-induced sensitization and tolerance: behavioral characteristics, developmental impacts, and neurobiological mechanisms. J Psychopharmacol. 2016;30:749\u201370.","journal-title":"J Psychopharmacol"},{"key":"4061_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00213-010-1925-5","volume":"212","author":"M Li","year":"2010","unstructured":"Li M, Sun T, Zhang C, Hu G. Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl). 2010;212:45\u201357.","journal-title":"Psychopharmacology (Berl)"},{"key":"4061_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0731-7085(93)E0020-N","volume":"13","author":"EO Fadiran","year":"1995","unstructured":"Fadiran EO, Leslie J, Fossler M, Young D. Determination of clozapine and its major metabolites in human serum and rat plasma by liquid chromatography using solid-phase extraction and ultraviolet detection. J Pharm Biomed Anal. 1995;13:185\u201390.","journal-title":"J Pharm Biomed Anal"},{"key":"4061_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/npp.1993.50","volume":"9","author":"RJ Baldessarini","year":"1993","unstructured":"Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology. 1993;9:117\u201324.","journal-title":"Neuropsychopharmacology"},{"key":"4061_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0014-2999(00)00277-6","volume":"398","author":"L Sun","year":"2000","unstructured":"Sun L, Lau CE. Intravenous and oral clozapine pharmacokinetics, pharmacodynamics, and concentration-effect relations: acute tolerance. Eur J Pharmacol. 2000;398:225\u201338.","journal-title":"Eur J Pharmacol"},{"key":"4061_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","volume":"31","author":"HN Boyda","year":"2010","unstructured":"Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci. 2010;31:484\u201397.","journal-title":"Trends Pharmacol Sci"},{"key":"4061_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000100981","volume":"85","author":"G Tulipano","year":"2007","unstructured":"Tulipano G, Rizzetti C, Bianchi I, Fanzani A, Spano P, Cocchi D. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology. 2007;85:61\u201370.","journal-title":"Neuroendocrinology"},{"key":"4061_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.phrs.2008.08.002","volume":"58","author":"JL Wiley","year":"2008","unstructured":"Wiley JL, Evans RL. Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats. Pharmacol Res. 2008;58:240\u20136.","journal-title":"Pharmacol Res"},{"key":"4061_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120474","volume":"600","author":"HP Patel","year":"2021","unstructured":"Patel HP, Chaudhari PS, Gandhi PA, Desai BV, Desai DT, Dedhiya PP, et al. Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies. Int J Pharm. 2021;600:120474.","journal-title":"Int J Pharm"},{"key":"4061_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107717","volume":"175","author":"JWY Yuen","year":"2020","unstructured":"Yuen JWY, Wu C, Wang CK, Kim DD, Procyshyn RM, Honer WG, et al. A comparison of the effects of clozapine and its metabolite norclozapine on metabolic dysregulation in rodent models. Neuropharmacology. 2020;175:107717.","journal-title":"Neuropharmacology"},{"issue":"Suppl 1","key":"4061_CR36","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1\u201393.","journal-title":"CNS Drugs"},{"key":"4061_CR37","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.psyneuen.2007.05.007","volume":"32","author":"M Murashita","year":"2007","unstructured":"Murashita M, Kusumi I, Hosoda H, Kangawa K, Koyama T. Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats. Psychoneuroendocrinology. 2007;32:777\u201384.","journal-title":"Psychoneuroendocrinology"},{"key":"4061_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.schres.2014.05.003","volume":"157","author":"GC Smith","year":"2014","unstructured":"Smith GC, Zhang ZY, Mulvey T, Petersen N, Lach S, Xiu P, et al. Clozapine directly increases insulin and glucagon secretion from islets: implications for impairment of glucose tolerance. Schizophr Res. 2014;157:128\u201333.","journal-title":"Schizophr Res"},{"key":"4061_CR39","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1007\/s00125-006-0446-6","volume":"49","author":"N Sasaki","year":"2006","unstructured":"Sasaki N, Iwase M, Uchizono Y, Nakamura U, Imoto H, Abe S, et al. The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets. Diabetologia. 2006;49:2930\u20138.","journal-title":"Diabetologia"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04061-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04061-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:02:34Z","timestamp":1784044954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04061-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4061"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04061-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7097479\/v1","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"360"}}